Variable | PF score | RP score | BP score | GH score | VT score | SF score | RE score | MH score | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
Sex (man vs. woman) | 1.611 (0.786–3.302) | 0.193 | 1.419 (0.692–2.909) | 0.339 | 0.737 (0.337–1.613) | 0.446 | 0.884 (0.421–1.885) | 0.744 | 0.861 (0.428–1.730) | 0.674 | 0.955 (0.476–1.917) | 0.898 | 1.673 (0.796–3.513) | 0.174 | 0.850 (0.423–1.710) | 0.649 |
Age (<65 vs. ≥65 years) | 0.689 (0.347–1.402) | 0.312 | 0.821 (0.401–1.680) | 0.589 | 0.721 (0.329–1.580) | 0.414 | 0.794 (0.378–1.665) | 0.541 | 1.636 (0.802–3.337) | 0.176 | 0.814 (0.406–1.632) | 0.562 | 1.033 (0.506–2.109) | 0.929 | 1.310 (0.61–2.636) | 0.449 |
MSKCC grade (favorable vs. others) | 1.184 (0.441–3.179 | 0.738 | 2.557 (0.905–7.339) | 0.076 | 1.089 (0.371–3.195) | 0.877 | 1.927 (0.721–5.153) | 0.191 | 0.887 (0.334–2.357) | 0.811 | 1.939 (0.714–5.265) | 0.194 | 1.128 (0.413–3.085) | 0.814 | 0.804 (0.305–2.122) | 0.660 |
IMDC risk (good vs. others) | 0.689 (0.347–1.402) | 0.713 | 0.202 (0.041–1.003) | 0.050 | 0.465 (0.371–3.195) | 0.399 | 0.665 (0.157–2.809) | 0.579 | 0.454 (0.109–1.887) | 0.277 | 0.527 (0.129–2.157) | 0.373 | 1.077 (0.258–4.499) | 0.919 | 1.529 (0.383–6.104) | 0.548 |
AE grade (1–2 vs. 3–4) | 0.699 (0.268–1.828) | 0.465 | 3.711 (1.263–10.910) | 0.017 | 4.259 (1.561–11.622) | 0.005 | 1.411 (0.532–3.747) | 0.489 | 0.758 (0.289–1.989) | 0.573 | 1.718 (0.641–4.603) | 0.282 | 2.035 (0.695–5.960) | 0.329 | 2.465 (0.889–6.835) | 0.083 |
Treatment (sorafenib vs. sunitinib) | 1.141 (0.620–2.099) | 0.671 | 1.001 (0.539–1.859) | 0.998 | 1.335 (0.694–2.568) | 0.387 | 0.595 (0.311–1.139 | 0.117 | 0.735 (0.401–1.348) | 0.320 | 1.033 (0.564–1.890) | 0.917 | 1.364 (0.731–2.545) | 0.721 | 1.340 (0.730–3.462) | 0.345 |